Aim To evaluate the percentages of achieving lipid-lowing targets and the safety of different doses of atorvastatin in hypercholesterol patients of different cardiovascular risk stratifications. Methods From February to July in 2012, we enrolled 122 patients who were diagnosed as hypercholesterolemia in outpatient of our hospital as experimental group, and they were 50～70 years old, 77 men and 45 female. All patients in experimental group were assigned in the low risk group （n＝29）, intermediate risk group （n＝33）, high risk group （n＝32） and very high risk group （n＝28） according to the stratifications of their cardiovascular risk factors. The patients in the above four groups were given different initial dosages of atorvastatin according to the low density lipoprotein cholesterol （LDLC） levels and their cardiovascular risk stratifications, and for those whose LDLC levels didnt achieve lipid-lowing targets after 6 weeks of treatment 10 mg atorvastatin would be added. There were 39 patients with hypercholesterolemia in that same period who were enrolled as control group, all of them were given routine dosage of atorvastatin every day, and for those whose LDLC didnt achieve lip-